1
|
Sanchis J, Bueno H, García-Blas S, Alegre O, Martí D, Martínez-Sellés M, Domínguez-Pérez L, Díez-Villanueva P, Barrabés JA, Marín F, Villa A, Sanmartín M, Llibre C, Sionís A, Carol A, Fernández-Cisnal A, Calvo E, Morales MJ, Elízaga J, Gómez I, Alfonso F, García del Blanco B, Formiga F, Núñez E, Núñez J, Ariza-Solé A. Invasive Treatment Strategy in Adults With Frailty and Non-ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open 2024; 7:e240809. [PMID: 38446482 PMCID: PMC10918507 DOI: 10.1001/jamanetworkopen.2024.0809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Accepted: 01/10/2024] [Indexed: 03/07/2024] Open
Abstract
Importance The MOSCA-FRAIL randomized clinical trial compared invasive and conservative treatment strategies in patients with frailty with non-ST-segment elevation myocardial infarction (NSTEMI). It showed no differences in the number of days alive and out of the hospital at 1 year. Objective To assess the outcomes of the MOSCA-FRAIL trial during extended follow-up. Design, Setting, and Participants The MOSCA-FRAIL randomized clinical trial was conducted at 13 hospitals in Spain between July 7, 2017, and January 9, 2021, and included 167 adults (aged ≥70 years) with frailty (Clinical Frailty Scale score ≥4) and NSTEMI. In this preplanned secondary analysis, follow-up was extended to January 31, 2023. Data analysis was performed from April 5 to 29, 2023, using the intention-to-treat principle. Interventions Patients were randomized to a routine invasive (coronary angiography and revascularization if feasible [n = 84]) or a conservative (medical treatment with coronary angiography only if recurrent ischemia [n = 83]) strategy. Main outcomes and measures The primary end point was the difference in restricted mean survival time (RMST). Secondary end points included readmissions for any cause, considering recurrent readmissions. Results Among the 167 patients included in the analysis, the mean (SD) age was 86 (5) years; 79 (47.3%) were men and 88 (52.7%) were women. A total of 93 deaths and 367 readmissions accrued. The RMST for all-cause death over the entire follow-up was 3.13 (95% CI, 2.72-3.60) years in the invasive and 3.06 (95% CI, 2.84-3.32) years in the conservative treatment groups. The RMST analysis showed inconclusive differences in survival time (invasive minus conservative difference, 28 [95% CI, -188 to 230] days). Patients under invasive treatment tended to have shorter survival in the first year (-28 [95% CI, -63 to 7] days), which improved after the first year (192 [95% CI, 90-230] days). Kaplan-Meier mortality curves intersected, displaying higher mortality to 1 year in the invasive group that shifted to a late benefit (landmark analysis hazard ratio, 0.58 [95% CI, 0.33-0.99]; P = .045). Early harm was more evident in the subgroup with a Clinical Frailty Scale score greater than 4. No differences were found for the secondary end points. Conclusions and Relevance In this extended follow-up of a randomized clinical trial of patients with frailty and NSTEMI, an invasive treatment strategy did not improve outcomes at a median follow-up of 1113 (IQR, 443-1441) days. However, a differential distribution of deaths was observed, with early harm followed by later benefit. The phenomenon of depletion of susceptible patients may be responsible for this behavior. Trial registration ClinicalTrials.gov Identifier: NCT03208153.
Collapse
Affiliation(s)
- Juan Sanchis
- Cardiology Department, University Clinic Hospital of València, University of València, Instituto de Investigación Sanitaria Clínico Valencia, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Valencia, Spain
| | - Héctor Bueno
- Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
- Cardiology Department, Universisty Hospital 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERCV, Madrid, Spain
- Complutense University, Madrid, Spain
| | - Sergio García-Blas
- Cardiology Department, University Clinic Hospital of València, University of València, Instituto de Investigación Sanitaria Clínico Valencia, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Valencia, Spain
| | - Oriol Alegre
- Cardiology Department, University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
| | - David Martí
- Central Defense Hospital, Alcalá University, Madrid, Spain
| | - Manuel Martínez-Sellés
- Cardiology Department, University Hospital Gregorio Marañón, CIBERCV, Complutense University, European University, Madrid, Spain
| | - Laura Domínguez-Pérez
- Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
- Cardiology Department, Universisty Hospital 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERCV, Madrid, Spain
- Complutense University, Madrid, Spain
| | - Pablo Díez-Villanueva
- University Hospital La Princesa, Autonomous University of Madrid, Instituto de Investigación Sanitaria Princesa, CIBERCV, Madrid, Spain
| | | | - Francisco Marín
- University Hospital Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria–Arrixaca, CIBERCV, El Palmar, Murcia, Spain
| | - Adolfo Villa
- Southeast University Hospital, Arganda del Rey, Madrid, Spain
| | | | - Cinta Llibre
- University Hospital Germans Trias i Pujol, CIBERCV, Badalona, Barcelona, Spain
| | | | - Antoni Carol
- Moisés Broggi Hospital, Sant Joan Despí, Barcelona, Spain
| | - Agustín Fernández-Cisnal
- Cardiology Department, University Clinic Hospital of València, University of València, Instituto de Investigación Sanitaria Clínico Valencia, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Valencia, Spain
| | - Elena Calvo
- Cardiology Department, University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
| | | | - Jaime Elízaga
- Cardiology Department, University Hospital Gregorio Marañón, CIBERCV, Complutense University, European University, Madrid, Spain
| | - Iván Gómez
- Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
- Cardiology Department, Universisty Hospital 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERCV, Madrid, Spain
- Complutense University, Madrid, Spain
| | - Fernando Alfonso
- University Hospital La Princesa, Autonomous University of Madrid, Instituto de Investigación Sanitaria Princesa, CIBERCV, Madrid, Spain
| | | | - Francesc Formiga
- Cardiology Department, University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Eduardo Núñez
- Cardiology Department, University Clinic Hospital of València, University of València, Instituto de Investigación Sanitaria Clínico Valencia, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Valencia, Spain
| | - Julio Núñez
- Cardiology Department, University Clinic Hospital of València, University of València, Instituto de Investigación Sanitaria Clínico Valencia, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Valencia, Spain
| | - Albert Ariza-Solé
- Cardiology Department, University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
2
|
García-Touchard A, Sabaté M, Gonzalo N, Peral V, Vaquerizo B, Ruiz-Salmerón R, García del Blanco B, Jiménez-Mazuecos J, Molina E, Martínez-Romero P, Hernandez-García JM, Ruiz-Quevedo V, Urbano C, Fernández-Portales J, Rumoroso JR, Casanova-Sandoval J, Pinar E, Lopez-Pais J, Oteo JF, Alfonso F. Very long-term efficacy and safety of paclitaxel-eluting balloon after a bare-metal stent for the treatment of ST-elevation myocardial infarction: 8-year results of a randomized clinical trial (PEBSI study). Cardiovasc Diagn Ther 2023; 13:792-804. [PMID: 37941845 PMCID: PMC10628420 DOI: 10.21037/cdt-22-623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Accepted: 09/08/2023] [Indexed: 11/10/2023]
Abstract
Background Drug-eluting stents (DES) are considered the therapy of choice in ST-segment elevation myocardial infarction (STEMI); however, a low persistent rate of revascularizations and stent thrombosis exist over the time. We have previously shown that a paclitaxel (PTX)-drug-coated balloon (DCB) after a bare-metal stent (BMS) implantation (DCB-combined strategy) yields superior angiographic and clinical results compared to BMS in the short term. However, the long-term safety and efficacy of this approach remain uncertain. Methods An 8-year clinical follow-up was conducted on patients enrolled in the randomized PEBSI-1 trial (NCT01839890). The original trial included patients who suffered a STEMI, patients were randomly assigned to receive a DCB-combined strategy or BMS only and the primary endpoint was in-stent late luminal loss (LLL) at 9-month follow-up. After the completion of this study, death, myocardial re-infarction, ischemia-driven repeated revascularizations included target lesion revascularization (TLR) and target vessel revascularization (TVR), and stent thrombosis, were assessed by yearly contact by a clinical visit, telephone or by electronic records. These outcomes were adhered to ARC-2 criteria. Results The rate of incomplete follow-up was very low, with only 3 out of 111 patients (2.7%) in the DCB-combined strategy group and 1 out of 112 patients (0.9%) in the BMS group. At 8 years there were a lower rate of TVR [3.7% vs. 14.3%; hazard ratio (HR): 0.243; 95% confidence interval (CI): 0.081-0.727; P=0.006], and a trend towards lower TLR (2.8% vs. 8.9%; HR: 0.300; 95% CI: 0.083-1.090; P=0.052) in the DCB-combined strategy group. No statistical difference between the DCB-combined strategy and BMS groups were found for all causes of death, deaths from cardiovascular disease, reinfarctions or stent thrombosis. Notably in the DCB-combined strategy group, no episode of stent thrombosis occurred after the first year. Similarly, there were no cardiovascular deaths, TVR and TLR in the DCB-combined strategy group after 5 years. In contrast, during the period from year 5 to 8, the BMS group experienced an additional cardiovascular death, as well as one case of TVR, one case of TLR, and one case of stent thrombosis. Conclusions In STEMI patients, the DCB-combined strategy maintains its safety and clinical efficacy over time. Our rates of TVR, TLR, and very late stent thrombosis (VLST) at very long-term are the lowest ever found in a STEMI trial. Further studies are warranted to assess the potential superiority of this novel strategy as compared with new-generation DES to prevent very late events in these patients. Trial Registration ClinicalTrials.gov; identifier: NCT01839890.
Collapse
Affiliation(s)
- Arturo García-Touchard
- Department of Interventional Cardiology, Hospital Universitario Puerta De Hierro Majadahonda, Madrid, Spain
| | - Manel Sabaté
- Department of Interventional Cardiology, Hospital Clinic i Provincial, Barcelona, Spain
| | - Nieves Gonzalo
- Department of Interventional Cardiology, Hospital Clínico San Carlos, Madrid, Spain
| | - Vicente Peral
- Department of Interventional Cardiology, Health Research Institute of the Balearic Islands (IdISBa), Hospital Universitari Son Espases, Palma de Mayorca, Spain
| | - Beatriz Vaquerizo
- Department of Interventional Cardiology, Hospital Del Mar, Barcelona, Spain
| | - Rafael Ruiz-Salmerón
- Department of Interventional Cardiology, Hospital Virgen Macarena, Sevilla, Spain
| | - Bruno García del Blanco
- Department of Interventional Cardiology, Hospital Universitari Vall D’Hebron, Barcelona, Spain
| | - Jesús Jiménez-Mazuecos
- Department of Interventional Cardiology, Complejo Hospitalario Universitario De Albacete, Albacete, Spain
| | - Eduardo Molina
- Department of Interventional Cardiology, Hospital Universitario Virgen De Las Nieves, Granada, Spain
| | | | | | - Valeriano Ruiz-Quevedo
- Department of Interventional Cardiology, Hospital Universitario De Navarra, Pamplona, Spain
| | - Cristóbal Urbano
- Department of Interventional Cardiology, Hospital Carlos Haya, Málaga, Spain
| | | | - José Ramón Rumoroso
- Department of Interventional Cardiology, Hospital De Galdakao, Bizkaia, Spain
| | | | - Eduardo Pinar
- Department of Interventional Cardiology, Hospital Virgen De La Arrixaca, Murcia, Spain
| | - Javier Lopez-Pais
- Department of Interventional Cardiology, Hospital Clínico Universitario De Santiago, La Coruña, Spain
| | - Juan Francisco Oteo
- Department of Interventional Cardiology, Hospital Universitario Puerta De Hierro Majadahonda, Madrid, Spain
| | - Fernando Alfonso
- Department of Interventional Cardiology, Hospital Universitario de La Princesa, Madrid, Spain
| |
Collapse
|
3
|
Sanchis J, Bueno H, Miñana G, Guerrero C, Martí D, Martínez-Sellés M, Domínguez-Pérez L, Díez-Villanueva P, Barrabés JA, Marín F, Villa A, Sanmartín M, Llibre C, Sionís A, Carol A, García-Blas S, Calvo E, Morales Gallardo MJ, Elízaga J, Gómez-Blázquez I, Alfonso F, García del Blanco B, Núñez J, Formiga F, Ariza-Solé A. Effect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non-ST-Segment Elevation Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA Intern Med 2023; 183:407-415. [PMID: 36877502 PMCID: PMC9989957 DOI: 10.1001/jamainternmed.2023.0047] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Accepted: 01/09/2023] [Indexed: 03/07/2023]
Abstract
Importance To our knowledge, no randomized clinical trial has compared the invasive and conservative strategies in frail, older patients with non-ST-segment elevation acute myocardial infarction (NSTEMI). Objective To compare outcomes of invasive and conservative strategies in frail, older patients with NSTEMI at 1 year. Design, Setting, and Participants This multicenter randomized clinical trial was conducted at 13 Spanish hospitals between July 7, 2017, and January 9, 2021, and included 167 older adult (≥70 years) patients with frailty (Clinical Frailty Scale score ≥4) and NSTEMI. Data analysis was performed from April 2022 to June 2022. Interventions Patients were randomized to routine invasive (coronary angiography and revascularization if feasible; n = 84) or conservative (medical treatment with coronary angiography for recurrent ischemia; n = 83) strategy. Main Outcomes and Measures The primary end point was the number of days alive and out of the hospital (DAOH) from discharge to 1 year. The coprimary end point was the composite of cardiac death, reinfarction, or postdischarge revascularization. Results The study was prematurely stopped due to the COVID-19 pandemic when 95% of the calculated sample size had been enrolled. Among the 167 patients included, the mean (SD) age was 86 (5) years, and mean (SD) Clinical Frailty Scale score was 5 (1). While not statistically different, DAOH were about 1 month (28 days; 95% CI, -7 to 62) greater for patients managed conservatively (312 days; 95% CI, 289 to 335) vs patients managed invasively (284 days; 95% CI, 255 to 311; P = .12). A sensitivity analysis stratified by sex did not show differences. In addition, we found no differences in all-cause mortality (hazard ratio, 1.45; 95% CI, 0.74-2.85; P = .28). There was a 28-day shorter survival in the invasive vs conservatively managed group (95% CI, -63 to 7 days; restricted mean survival time analysis). Noncardiac reasons accounted for 56% of the readmissions. There were no differences in the number of readmissions or days spent in the hospital after discharge between groups. Neither were there differences in the coprimary end point of ischemic cardiac events (subdistribution hazard ratio, 0.92; 95% CI, 0.54-1.57; P = .78). Conclusions and Relevance In this randomized clinical trial of NSTEMI in frail older patients, there was no benefit to a routine invasive strategy in DAOH during the first year. Based on these findings, a policy of medical management and watchful observation is recommended for older patients with frailty and NSTEMI. Trial Registration ClinicalTrials.gov Identifier: NCT03208153.
Collapse
Affiliation(s)
- Juan Sanchis
- Cardiology Department, University Clinic Hospital of València, University of València, INCLIVA, CIBERCV, València, Spain
| | - Héctor Bueno
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Cardiology Department, Universisty Hospital 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, CIBERCV, Madrid, Spain, Complutense University, Madrid, Spain
| | - Gema Miñana
- Cardiology Department, University Clinic Hospital of València, University of València, INCLIVA, CIBERCV, València, Spain
| | - Carme Guerrero
- Cardiology Department, University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
| | - David Martí
- Central Defense Hospital, Madrid, Alcalá University, Madrid, Spain
| | - Manuel Martínez-Sellés
- Cardiology Department, University Hospital Gregorio Marañón, CIBERCV, Complutense University, European University, Madrid, Spain
| | - Laura Domínguez-Pérez
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Cardiology Department, Universisty Hospital 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, CIBERCV, Madrid, Spain, Complutense University, Madrid, Spain
| | - Pablo Díez-Villanueva
- University Hospital La Princesa, Autonomous University of Madrid, IIS-IP, CIBERCV Madrid, Spain
| | | | - Francisco Marín
- University Hospital Virgen de la Arrixaca, IMIB-Arrixaca, CIBERCV, El Palmar, Murcia, Spain
| | - Adolfo Villa
- Southeast University Hospital, Arganda del Rey, Madrid, Spain
| | | | - Cinta Llibre
- University Hospital Germans Trias i Pujol, CIBERCV, Badalona, Barcelona, Spain
| | | | - Antoni Carol
- Moisés Broggi Hospital, Sant Joan Despí, Barcelona, Spain
| | - Sergio García-Blas
- Cardiology Department, University Clinic Hospital of València, University of València, INCLIVA, CIBERCV, València, Spain
| | - Elena Calvo
- Cardiology Department, University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
| | | | - Jaime Elízaga
- Cardiology Department, University Hospital Gregorio Marañón, CIBERCV, Complutense University, European University, Madrid, Spain
| | - Iván Gómez-Blázquez
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain, Cardiology Department, Universisty Hospital 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, CIBERCV, Madrid, Spain, Complutense University, Madrid, Spain
| | - Fernando Alfonso
- University Hospital La Princesa, Autonomous University of Madrid, IIS-IP, CIBERCV Madrid, Spain
| | | | - Julio Núñez
- Cardiology Department, University Clinic Hospital of València, University of València, INCLIVA, CIBERCV, València, Spain
| | - Francesc Formiga
- Cardiology Department, University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
| | - Albert Ariza-Solé
- Cardiology Department, University Hospital of Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
| |
Collapse
|
4
|
Vázquez Rodríguez JM, Pinar Bermúdez E, Luis Zamorano J, Moreu Burgos J, Díaz-Fernández JF, del Blanco BG, Sarmah A, Candolfi P, Shore y J, Green M. Coste-efectividad del implante percut�neo de v�lvula a�rtica con SAPIEN 3 en pacientes con bajo riesgo de mortalidad quir�rgica en Espa�a. RECIC 2022. [DOI: 10.24875/recic.m22000337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
5
|
Rodriguez-Leor O, de la Torre Hernández JM, García-Camarero T, García del Blanco B, López-Palop R, Fernández-Nofrerías E, Cuellas Ramón C, Jiménez-Kockar M, Jiménez-Mazuecos J, Fernández Salinas F, Gómez-Lara J, Brugaletta S, Alfonso F, Palma R, Gómez-Menchero AE, Millán R, Tejada Ponce D, Linares Vicente JA, Ojeda S, Pinar E, Fernández-Pelegrina E, Morales-Ponce FJ, Cid-Álvarez AB, Rama-Merchan JC, Molina Navarro E, Escaned J, Pérez de Prado A. Instantaneous Wave-Free Ratio for the Assessment of Intermediate Left Main Coronary Artery Stenosis: Correlations With Fractional Flow Reserve/Intravascular Ultrasound and Prognostic Implications: The iLITRO-EPIC07 Study. Circ Cardiovasc Interv 2022; 15:861-871. [PMID: 36111801 PMCID: PMC9648986 DOI: 10.1161/circinterventions.122.012328] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
BACKGROUND There is little information available on agreement between fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) in left main coronary artery (LMCA) intermediate stenosis. Besides, several meta-analyses support the use of FFR to guide LMCA revascularization, but limited information is available on iFR in this setting. Our aims were to establish the concordance between FFR and iFR in intermediate LMCA lesions, to evaluate with intravascular ultrasound (IVUS) in cases of FFR/iFR discordance, and to prospectively validate the safety of deferring revascularization based on a hybrid decision-making strategy combining iFR and IVUS. METHODS Prospective, observational, multicenter registry with 300 consecutive patients with intermediate LMCA stenosis who underwent FFR and iFR and, in case of discordance, IVUS and minimal lumen area measurements. Primary clinical end point was a composite of cardiovascular death, LMCA lesion-related nonfatal myocardial infarction, or unplanned LMCA revascularization. RESULTS FFR and iFR had an agreement of 80% (both positive in 67 and both negative in 167 patients); in case of disagreement (31 FFR+/iFR- and 29 FFR-/iFR+) minimal lumen area was ≥6 mm2 in 8.7% of patients with FFR+ and 14.6% with iFR+. Among the 300 patients, 105 (35%) underwent revascularization and 181 (60%) were deferred according to iFR and IVUS. At a median follow-up of 20 months, major adverse cardiac events incidence was 8.3% in the defer group and 13.3% in the revascularization group (hazard ratio, 0.71 [95% CI 0.30-1.72]; P=0.45). CONCLUSIONS In patients with intermediate LMCA stenosis, a physiology-guided treatment decision is feasible either with FFR or iFR with moderate concordance between both indices. In case of disagreement, the use of IVUS may be useful to indicate revascularization. Deferral of revascularization based on iFR appears to be safe in terms of major adverse cardiac events. REGISTRATION URL: https://www. CLINICALTRIALS gov; Unique identifier: NCT03767621.
Collapse
Affiliation(s)
- Oriol Rodriguez-Leor
- Institut del Cor, Hospital Universitari Germans Trias i Pujol, Badalona, Spain (O.R.-L., E.F.-N.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain (O.R.-L., E.F.-N., A.B.C.-A.).,Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain (O.R.-L., E.F.-N.)
| | - José María de la Torre Hernández
- Cardiology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain (J.M.d.l.T.H., T.G.-C.).,Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.d.l.T.H., T.G.-C.)
| | - Tamara García-Camarero
- Cardiology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain (J.M.d.l.T.H., T.G.-C.).,Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain (J.M.d.l.T.H., T.G.-C.)
| | - Bruno García del Blanco
- Cardiology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain (B.G.d.B., R.P.)
| | - Ramón López-Palop
- Cardiology Department, Hospital Virgen de la Arrixaca, Murcia, Spain (R.L.-P., E.P.)
| | - Eduard Fernández-Nofrerías
- Institut del Cor, Hospital Universitari Germans Trias i Pujol, Badalona, Spain (O.R.-L., E.F.-N.).,Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain (O.R.-L., E.F.-N., A.B.C.-A.)
| | - Carlos Cuellas Ramón
- Servicio de Cardiología, Hospital Universitario de León, Spain (C.C.R., A.P.d.P.)
| | - Marcelo Jiménez-Kockar
- Cardiology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (M.J.-K., E.F.-P.)
| | - Jesús Jiménez-Mazuecos
- Servicio de Cardiología, Complejo Hospitalario Universitario de Albacete, Spain (J.J.-M.)
| | | | - Josep Gómez-Lara
- Cardiology Department, Hospital Universitari de Bellvitge, L’Hospital de Llobregat, Spain (J.G.-L.)
| | - Salvatore Brugaletta
- Cardiology Department, Hospital Clínic, Barcelona, Spain (S.B.).,Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (S.B.).,University of Barcelona, Spain (S.B.)
| | - Fernando Alfonso
- Cardiology Department, Hospital de la Princesa, Madrid, Spain (F.A.)
| | - Ricardo Palma
- Cardiology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain (B.G.d.B., R.P.)
| | | | - Raúl Millán
- Cardiology Department, Hospital del Mar, Barcelona, Spain (R.M.)
| | - David Tejada Ponce
- Cardiology Department, Hospital General Universitario de Castellón, Castellón de la Plana, Spain (D.T.P.)
| | | | - Soledad Ojeda
- Division of Interventional Cardiology, Hospital Universitario Reina Sofía, Córdoba, Spain (S.O.)
| | - Eduardo Pinar
- Cardiology Department, Hospital Virgen de la Arrixaca, Murcia, Spain (R.L.-P., E.P.)
| | | | - Francisco J. Morales-Ponce
- University of Cordoba, Cordoba, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Spain (S.O.) Cardiology Department, Hospital Universitario de Puerto Real, Spain (F.J.M.-P.)
| | - Ana Belén Cid-Álvarez
- Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain (O.R.-L., E.F.-N., A.B.C.-A.).,Servicio de Cardiología, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain (A.B.C.-A.)
| | | | | | - Javier Escaned
- Cardiology Department, Hospital Clínico San Carlos, Madrid, Spain (J.E.).,Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdSSC), Madrid, Spain (J.E.).,Universidad Complutense de Madrid, Spain (J.E.)
| | | |
Collapse
|
6
|
del Blanco BG, Gómez Lara J, Rama Merchán JC, Goncalves-Ramírez LR, Otaegui Irurueta I, Bosch Peligero E, Carballo Garrido J, Palazuelos Molinero J, Bullones Ramírez JA, Casanova Sandoval J, Rumoroso Cuevas JR, Calle Pérez G, Fernández Nofrerías E, Ramírez y MÁC, de Prado AP. Estudio observacional prospectivo EPIC03-BIOSS. An�lisis del <i>stent</i> dedicado BIOSS LIM C en angioplastias en bifurcaci�n. RECIC 2022. [DOI: 10.24875/recic.m22000310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
7
|
Fernández-Rodríguez D, Casanova-Sandoval J, Barriuso I, Rivera K, Otaegui I, del Blanco BG, Jiménez TG, López-Pérez M, Rodríguez-Esteban M, Torres-Saura F, Díaz VJ, Ocaranza-Sánchez R, Disdier VP, Elvira GS, Worner F. Ajustando a RFR por Preditores de Discordância, “A RFR Ajustada”: Uma Metodologia Alternativa para Melhorar a Capacidade Diagnóstica dos Índices Coronarianos. Arq Bras Cardiol 2022; 119:705-713. [DOI: 10.36660/abc.20220176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2022] [Accepted: 06/15/2022] [Indexed: 01/10/2023] Open
|
8
|
del Blanco BG. Tratamiento percut�neo de trombosis valvular prot�sica recurrente. �C�mo lo har�a? RECIC 2022. [DOI: 10.24875/recic.m20000142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
9
|
Domingo Ribas E, Guindo J, Calviño Santos R, Otaegui I, Antoni Gómez J, Carrillo Suárez X, Sánchez J, Andraka L, Torres A, Casanova-Sandoval J, Ocaranza Sánchez R, León Jiménez J, Francisco Muñoz J, Trillo Nouche R, Fuertes y M, del Blanco BG. Seguimiento cl�nico del stent coronario largo no c�nico de sirolimus en el mundo real en lesiones de novo. Registro Billar. RECIC 2022. [DOI: 10.24875/recic.m21000248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
10
|
de Prado AP, Ocaranza-Sánchez R, Ruiz-Poveda FL, Moreu Burgos J, Álvarez Ramos R, Rodrigues A, Fernández González L, Aguar P, del Blanco BG, Pinar E, Peral V, Sainz Laso F, Ramón Rumoroso J, Torres A, Sabaté y M, Trillo Nouche R. Registro prospectivo del stent liberador de sirolimus con pol�mero estable de fluoroacrilato Angiolite: estudio EPIC02 � RANGO. RECIC 2022. [DOI: 10.24875/recic.m21000219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
11
|
Rodríguez-Leor O, Torre-Hernández JMDL, García-Camarero T, López-Palop R, del Blanco BG, Carrillo X, Portero-Portaz JJ, Jiménez-Kockar M, Gómez-Lara J, Ojeda S, Alfonso F, Brugaletta S, del Viejo AP, Antonio Linares J, Fernández-Cisnal A, Vaquerizo B, Fernández-Salinas F, Díaz-Fernández JF, Rama-Merchán JC, Molina E, Muñoz-García É, Morales F, Trillo R, Tellería M, Rondán J, Avanzas P, Moreu J, Baz-Alonso JA, Hernández F, Escaned J, Sanchis J, Lozano F, Toledano B, Puigfel M, Sádaba y M, de Prado AP. Justificaci�n y dise�o del estudio Concordancia entre RFF e iFR en lesiones del tronco com�n. Estudio iLITRO-EPIC-07. RECIC 2022. [DOI: 10.24875/recic.m21000223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
12
|
Serra-Creus B, Palma-Carbajal R, Barrón-Molina y JL, del Blanco BG. Imagen en panal de abeja: �enfermedad en entramado o trombo recanalizado? RECIC 2022. [DOI: 10.24875/recic.m21000222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
13
|
Alfonso F, Cuesta J, Ojeda S, Camacho-Freire S, García del Blanco B, Vaquerizo B, Zueco J, Trillo R, Mauri J, Velázquez M, Córdoba-Soriano JG, Serra A, Navarro F, Pan M, Díaz J, Otaegui I, Salvatella N, De la TorreHernandez JM, Val DD, Bastante T, Rivero F. Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study). Am J Cardiol 2022; 162:31-40. [PMID: 34903344 DOI: 10.1016/j.amjcard.2021.09.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 09/04/2021] [Accepted: 09/08/2021] [Indexed: 02/03/2023]
Abstract
Currently, both drug-eluting stents (DES) and drug-eluting balloons are recommended in patients with in-stent restenosis (ISR) of metallic stents. However, the clinical results of repeated interventions in patients with restenosis of bioresorbable vascular scaffolds (BVS) remain unsettled. We sought to assess the results of interventions in patients with BVS-ISR as compared with those obtained in patients with ISR of DES and bare-metal stents (BMS). Restenosis Intrastent: Treatment of Bioresorbable Vascular Scaffolds Restenosis (RIBS VII) is a prospective multicenter study (23 Spanish sites) that included 117 consecutive patients treated for BVS-ISR. Inclusion/exclusion criteria were similar to those of previous RIBS studies. Patients in the RIBS IV (DES-ISR, n = 309) and RIBS V (BMS - ISR, n = 189) randomized trials, were used as controls. Most patients with BVS-ISR were treated with DES (76%). Patients with BVS-ISR were younger, had larger vessels, and after interventions had higher in-segment residual diameter stenosis (19 ± 13%, 15 ± 11%, 15 ± 12%, p <0.001) than those treated for DES-ISR and BMS-ISR, respectively. At 1-year clinical follow-up (obtained in 100% of patients) target lesion revascularization (6%) was similar to that seen in patients with DES-ISR and BMS-ISR (8.7% and 3.7%, p = 0.32). Freedom from death, myocardial infarction, and target vessel revascularization (primary clinical end point) was 8.5%, also similar to that found in patients with DES-ISR and BMS-ISR (14.2% and 7.4%, p = 0.09). Results were also similar when only patients treated with DES in each group were compared and remained unchanged after adjusting for potential confounders in baseline characteristics. Time to BVS-ISR did not influence angiographic or clinical results. This study demonstrates the safety and efficacy of coronary interventions for patients presenting with BVS-ISR. One-year clinical results in these patients are comparable to those seen in patients with ISR of metallic stents (ClinicalTrials.gov ID:NCT03167424).
Collapse
|
14
|
Romaguera R, Ojeda S, Cruz-González I, Moreno R, Guisado Rasco A, Gutiérrez-Barrios A, Gómez-Menchero A, Morales Ponce FJ, Sánchez Burguillos FJ, Oneto J, Caballero Borrego J, Sánchez Gila J, Bullones Ramírez JA, Fernández JC, Alonso Briales JH, Íñigo García LA, Vizcaíno Arellano M, Fajardo Molina R, Ojeda S, Ramírez-Moreno A, Suárez de Lezo J, García-Borbolla Fernández R, Camacho Freire SJ, Ballesteros Pradas SM, Lozano I, Avanzas P, Bango MJ, Bosa Ojeda F, Jiménez Cabrera FM, Martin Lorenzo P, Pimienta González R, Rihawi ZK, Zueco J, Sánchez Pérez I, Jiménez-Mazuecos J, Novo García E, Moreu Burgos J, Pérez de Prado A, Cruz-González I, Amat-Santos IJ, Robles Alonso J, Vaquerizo B, García del Blanco B, Bosch Peligero E, Roura G, Mohandes M, Bassaganyas J, Casanova-Sandoval JM, Sabaté M, Carrillo Suárez X, García Picart J, Muñoz Camacho JF, Carballo Garrido J, Sanchis J, Berenguer Jofresa A, Planas del Viejo AM, Frutos García A, Pomar Domingo F, Torres Saura F, Díez Gil JL, Ruiz Nodar JM, Jerez Valero M, Aguar P, Tejedor P, López Palop R, Mainar V, Merchán Herrera A, Fernández Portales J, Rama Merchán JC, Baz JA, Trillo Nouche R, Calviño Santos R, Ocaranza R, Peña G, Gómez Jaume A, Bethencourt A, Vera Pernasetti L, Portero Pérez MP, Sánchez-Recalde Á, Rivero Crespo F, Sarnago Cebada F, Elízaga J, Franco Peláez JA, Oteo Domínguez JF, García JR, Hernando Marrupé L, Pérez Vizcayno MJ, Moreno R, Sánchez-Aquino González R, Álvarez Antón S, Rubio Alonso B, Macaya C, Alegría Barrero E, García E, Hernández Hernández F, Palazuelos Molinero J, Unzué L, Vázquez Álvarez ME, Pinar Bermúdez E, Lacunza Ruiz FJ, Ruiz Quevedo V, Artaiz Urdaci M, Torres Bosco AM, Subinas Elorriaga A, Garcia San Román K, Saez Moreno R, Andraka L, Larman Tellechea M, Diarte de Miguel JA, Ruiz Arroyo JR. Spanish Cardiac Catheterization and Coronary Intervention Registry. 30th Official Report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2020) in the year of the COVID-19 pandemic. Revista Española de Cardiología (English Edition) 2021; 74:1095-1105. [PMID: 34782287 PMCID: PMC8552543 DOI: 10.1016/j.rec.2021.10.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/07/2021] [Accepted: 08/04/2021] [Indexed: 11/13/2022]
Abstract
Introduction and objectives The Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC) presents its annual activity report for 2020, the year of the coronavirus disease (COVID-19) pandemic. Methods All Spanish centers with catheterization laboratories were invited to participate. Data were collected online and were analyzed by an external company, together with the members of the ACI-SEC. Results A total of 123 centers participated (4 more than 2019), of which 83 were public and 40 were private. Diagnostic coronary angiograms decreased by 9.4%, percutaneous coronary interventions by 10.1%, primary percutaneous coronary interventions by 4.1%, transcatheter aortic valve replacements by 0.9%, and left atrial appendage closure by 8.3%. The only procedures that increased with respect to previous years were edge-to-edge mitral valve repair (13.8%) and patent foramen ovale closure (19.4%). The use of pressure wire (5.5%), intravascular imaging devices and plaque preparation devices decreased (with the exception of lithotripsy, which increased by 62%). Conclusions In the year of the COVID-19 pandemic, the registry showed a marked drop in activity in all procedures except for percutaneous mitral valve repair and patent foramen ovale closure. This decrease was less marked than previously described, suggesting a rebound in interventional activity after the first wave.
Collapse
|
15
|
Jiménez-Quevedo P, Nombela-Franco L, Muñoz-García E, del Valle-Fernández R, Trillo R, de la Torre Hernández JM, Salido L, Elizaga J, Ojeda S, Sánchez Gila J, García del Blanco B, Berenguer A, Lasa-Larraya G, Urbano Carrillo C, Albarrán A, Ruiz-Salmerón R, Moreu J, Gheorghe L, Arzamendi D, Yanes-Bowden G, Díaz J, Pérez-Moreiras I, Artaiz M, Vaquerizo B, Cruz-González I, Ruiz-Quevedo V, Blanco-Mata R, Baz JA, Villa M, Ortiz de Salazar Á, Tascón-Quevedo V, Casellas S, Moreno R. Resultados clínicos tempranos tras el implante percutáneo de válvula aórtica por acceso transaxilar comparado con el acceso transfemoral. Datos del registro español de TAVI. Rev Esp Cardiol 2021. [DOI: 10.1016/j.recesp.2021.07.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
16
|
Jiménez-Quevedo P, Muñoz-García A, Trillo-Nouche R, del Valle R, Torre Hernández JMDL, Salido L, Gutiérrez E, Pan M, Sánchez-Gila J, del Blanco BG, Moreno R, Blanco Mata R, Francisco Oteo J, Amat-Santos I, Regueiro A, Ten F, Manuel Nogales J, Fernández-Nofrerias E, Andraka L, Cruz Ferrer M, Pinar E, Romaguera R, Cuellas Ramón C, Alfonso F, García-Blas S, Piñero A, Ignasi J, Díaz Méndez R, Bordes P, Meseguer J, Nombela-Franco L, de TAVI RE. <i class="fa fa-video-camera" aria-hidden="true"></i> Evolución temporal en el tratamiento transcatéter de la estenosis aórtica: análisis del registro español de TAVI. RECIC 2021. [DOI: 10.24875/recic.m19000087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
17
|
Sabaté M, Okkels Jensen L, Tilsted HH, Moreno R, García del Blanco B, Macaya C, Pérez de Prado A, Cequier A, Pérez-Fuentes P, Schütte D, Costa R, Stoll HP, Flensted Lassen J. Thin- versus thick-strut polymer-free biolimus-eluting stents: the BioFreedom QCA randomised trial. EUROINTERVENTION 2021; 17:233-239. [PMID: 33433389 PMCID: PMC9724946 DOI: 10.4244/eij-d-20-01162] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
BACKGROUND The BioFreedom drug-coated stent with a stainless steel platform (BF-SS) has been demonstrated to be efficacious in patients at high bleeding risk and receiv-ing only one-month dual antiplatelet therapy. AIMS The aim of this study was to evaluate the efficacy of the new BioFreedom Ultra drug-coated stent with a thin-strut cobalt-chromium platform (BF-CoCr) compared to the BF-SS in an all-comers population undergoing percutaneous coronary intervention (PCI). METHODS This was a prospective, multicentre, non-inferiority trial. The primary endpoint was in-stent late lumen loss (LLL) as determined by quantitative coronary angiography at nine-month follow-up. Clinical evaluation was performed at one year. RESULTS A total of 200 patients were randomised (1:1) to either the BF-CoCr or the BF-SS stent at eight centres in Spain and Denmark. Baseline clinical and lesion characteristics were similar between the groups. Mean age was 66 years and 23% were female. The mean number of stents implanted per patient was 1.5. At nine-month follow-up, mean in-stent LLL was 0.34±0.49 mm in the BF-CoCr group versus 0.29±0.37 mm in the BF-SS group, p=0.005 for non-inferiority. At one year, target lesion failure was similar between the groups (7.3% in BF-CoCr vs 9.3% in the BF-SS group; p=0.60). CONCLUSIONS The BF-CoCr was non-inferior to the BF-SS in terms of in-stent LLL at nine months. Larger studies powered for clinical endpoints are warranted to compare the efficacy of this new platform with currently available DES.
Collapse
Affiliation(s)
- Manel Sabaté
- Interventional Cardiology Department, Cardiovascular Institute, Hospital Clínic, IDIBAPS, c/Villarroel 170, 08036 Barcelona, Spain
| | | | - Hans-Henrik Tilsted
- Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - Raul Moreno
- Hospital Universitario de la Paz, Madrid, Spain
| | | | | | | | - Angel Cequier
- Bellvitge University Hospital, University of Barcelona, IDIBELL, Barcelona, Spain
| | - Pedro Pérez-Fuentes
- Department of Interventional Cardiology, Cardiovascular Institute, Hospital Clinic IDIBAPS, Barcelona, Spain
| | | | - Ricardo Costa
- HCor, Associaçao Beneficente Siria, Sao Paolo, Brasil
| | | | - Jens Flensted Lassen
- Odense University Hospital, Odense, Denmark,Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
18
|
Otaegui Irurueta I, García del Blanco B, Martí Aguasca G. La pauta ultracorta de tratamiento antiagregante plaquetario doble de 1-3 meses tras el implante de stent liberador de fármacos o la conquista del polo sur. Rev Esp Cardiol 2021. [DOI: 10.1016/j.recesp.2020.08.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Gomez-Lara J, Ortega-Paz L, Brugaletta S, Cuesta J, Romaní S, Serra A, Salinas P, García del Blanco B, Goicolea J, Hernandez-Antolín R, Antuña P, Romaguera R, Regueiro A, Rivero F, Cequier À, Alfonso F, Gómez-Hospital JA, Sabaté M. Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial. EUROINTERVENTION 2020; 16:e913-e921. [DOI: 10.4244/eij-d-20-00198] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
20
|
Moreu J, Moreno-Gómez R, Pérez de Prado A, García del Blanco B, Trillo R, Pinar E, Molina E, Zueco J, Merchán A, Díaz-Fernández JF, Amat I. First-in-man randomised comparison of the Angiolite durable fluoroacrylate polymer-based sirolimus-eluting stent versus a durable fluoropolymer-based everolimus-eluting stent in patients with coronary artery disease: the ANGIOLITE trial. EUROINTERVENTION 2019; 15:e1081-e1089. [DOI: 10.4244/eij-d-19-00206] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
21
|
Limeres J, Lip GY, del Blanco BG, Ferreira-González I, Mutuberria M, Alfonso F, Bueno H, Cequier A, Prendergast B, Zueco J, Rodríguez-Leor O, Barrabés JA, García-Dorado D, Sambola A. Safety of drug-eluting stents compared to bare metal stents in patients with an indication for long-term oral anticoagulation: A propensity score matched analysis. Thromb Res 2019; 177:180-186. [DOI: 10.1016/j.thromres.2019.02.021] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2019] [Revised: 02/09/2019] [Accepted: 02/18/2019] [Indexed: 01/10/2023]
|
22
|
Brugaletta S, Cequier A, Alfonso F, Iñiguez A, Romaní S, Serra A, Salinas P, Goicolea J, Bordes P, del Blanco BG, Hernández-Antolín R, Pernigotti A, Gómez-Lara J, Sabaté M. MAGnesium-based bioresorbable scaffold and vasomotor function in patients with acute ST segment elevation myocardial infarction: The MAGSTEMI trial: Rationale and design. Catheter Cardiovasc Interv 2019; 93:64-70. [DOI: 10.1002/ccd.27825] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Affiliation(s)
- Salvatore Brugaletta
- Department of Cardiology, Institut Clínic Cardiovascular, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - Angel Cequier
- Department of Cardiology, Hospital de Bellvitge; Barcelona Spain
| | | | - Andrés Iñiguez
- Department of Cardiology, Hospital Alvaro Cunqueiro; Vigo Spain
| | - Sebastian Romaní
- Department of Cardiology, Hospital San Pedro de Alcántara; Cáceres Spain
| | - Antonio Serra
- Department of Cardiology, Hospital de Sant Pau; Barcelona Spain
| | - Pablo Salinas
- Department of Cardiology, Hospital Clínico San Carlos; Madrid Spain
| | - Javier Goicolea
- Department of Cardiology, Hospital Puerta de Hierro-Majadahonda; Madrid Spain
| | - Pascual Bordes
- Department of Cardiology, Hospital General de Alicante; Alicante Spain
| | | | | | - Alberto Pernigotti
- Department of Cardiology, Institut Clínic Cardiovascular, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| | - Josep Gómez-Lara
- Department of Cardiology, Hospital de Bellvitge; Barcelona Spain
| | - Manel Sabaté
- Department of Cardiology, Institut Clínic Cardiovascular, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); Barcelona Spain
| |
Collapse
|
23
|
Fischer Q, Himbert D, Webb JG, Eltchaninoff H, Muñoz-García AJ, Tamburino C, Nombela-Franco L, Nietlispach F, Moris C, Ruel M, Dager AE, Serra V, Cheema AN, Amat-Santos IJ, de Brito FS, Ribeiro H, Abizaid A, Sarmento-Leite R, Dumont E, Barbanti M, Durand E, Alonso Briales JH, Bouleti C, Immè S, Maisano F, del Valle R, Miguel Benitez L, García del Blanco B, Côté M, Philippon F, Urena M, Rodés-Cabau J. Impact of Preexisting Left Bundle Branch Block in Transcatheter Aortic Valve Replacement Recipients. Circ Cardiovasc Interv 2018; 11:e006927. [DOI: 10.1161/circinterventions.118.006927] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- Quentin Fischer
- Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Canada (Q.F., E.D., M.C., F.P., J.R.-C.)
| | - Dominique Himbert
- Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Canada (Q.F., E.D., M.C., F.P., J.R.-C.)
- Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, France (D.H., C.B., M.U.)
| | - John G. Webb
- Department of Cardiology, St. Paul’s Hospital, Vancouver, British Columbia Canada (J.G.W., M.B
| | - Helene Eltchaninoff
- Department of Cardiology, Hopital Charles Nicolle, University of Rouen, France (H.E., E.D.)
| | - Antonio J. Muñoz-García
- Department of Cardiology, Hospital Universitario Virgen de la Victoria, Universidad de Malaga, Spain (A.J.M.-G., J.H.A.B.)
| | - Corrado Tamburino
- Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (C.T., M.B., S.I.)
| | - Luis Nombela-Franco
- Instituto Cardiovascular, Hospital Clinico San Carlos, IdISSC, Madrid, Spain (L.N.-F.)
| | - Fabian Nietlispach
- Department of Cardiology, University Heart Center, Transcatheter Valve Clinic, Zurich, Switzerland (F.N., F.M.)
| | - Cesar Moris
- Department of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain (C.M., R.d.V.)
| | - Marc Ruel
- Department of Cardiology, Ottawa Heart Institute, University of Ottawa, Ontario, Canada (M.R.)
| | - Antonio E. Dager
- Department of Cardiology, Clinica de Occidente de Cali, Colombia (A.E.D., L.M.B.)
| | - Vicenç Serra
- Department of Cardiology, Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., B.G.d.B.)
| | - Asim N. Cheema
- Department of Cardiology, St. Michael’s Hospital, Toronto University, Ontario, Canada (A.N.C.)
| | - Ignacio J. Amat-Santos
- Department of Cardiology, Hospital Clinico Universitario de Valladolid, Spain (I.J.A.-S.)
| | - Fabio Sandoli de Brito
- Department of Cardiology, Hospital Israelita Albert Einstein, Sa.o Paulo, Brazil (F.S.d.B)
| | - Henrique Ribeiro
- Department of Cardiology, Heart Institute-InCor, University of Sa.o Paulo, Brazil (H.R.)
| | - Alexandre Abizaid
- Department of Cardiology, Instituto Dante Pazzanese de Cardiologia, Sa.o Paulo, Brazil (A.A.)
| | - Rogério Sarmento-Leite
- Department of Cardiology, Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, Brazil (R.S.-L.)
| | - Eric Dumont
- Department of Cardiology, Hopital Charles Nicolle, University of Rouen, France (H.E., E.D.)
| | - Marco Barbanti
- Department of Cardiology, St. Paul’s Hospital, Vancouver, British Columbia Canada (J.G.W., M.B
- Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (C.T., M.B., S.I.)
| | | | - Juan H. Alonso Briales
- Department of Cardiology, Hospital Universitario Virgen de la Victoria, Universidad de Malaga, Spain (A.J.M.-G., J.H.A.B.)
| | - Claire Bouleti
- Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, France (D.H., C.B., M.U.)
| | - Sebastiano Immè
- Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (C.T., M.B., S.I.)
| | - Francesco Maisano
- Department of Cardiology, University Heart Center, Transcatheter Valve Clinic, Zurich, Switzerland (F.N., F.M.)
| | - Raquel del Valle
- Department of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain (C.M., R.d.V.)
| | - Luis Miguel Benitez
- Department of Cardiology, Clinica de Occidente de Cali, Colombia (A.E.D., L.M.B.)
| | - Bruno García del Blanco
- Department of Cardiology, Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., B.G.d.B.)
| | - Mélanie Côté
- Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Canada (Q.F., E.D., M.C., F.P., J.R.-C.)
| | - François Philippon
- Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Canada (Q.F., E.D., M.C., F.P., J.R.-C.)
| | - Marina Urena
- Department of Cardiology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, France (D.H., C.B., M.U.)
| | - Josep Rodés-Cabau
- Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Canada (Q.F., E.D., M.C., F.P., J.R.-C.)
| |
Collapse
|
24
|
Díaz Fernández JF, Camacho Freire SJ, Fernández Guerrero JC, Delarche N, Bretelle C, Zueco Gil J, Palop RL, García del Blanco B, Mainar Tello V, Albert F. Everolimus drug‐eluting stent performance in patients with long coronary lesions: The multicenter Longprime registry. Catheter Cardiovasc Interv 2018; 92:E493-E501. [DOI: 10.1002/ccd.27657] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2017] [Revised: 04/04/2018] [Accepted: 04/15/2018] [Indexed: 11/09/2022]
Affiliation(s)
| | | | | | - Nicolas Delarche
- Department of CardiologyCentre Hospitalier Francois MitterandPau France
| | | | - Javier Zueco Gil
- Department of CardiologyMarques de Valdecilla HospitalSantander Spain
| | | | | | - Vicente Mainar Tello
- Department of CardiologyHospital General Universitario de AlicanteAlicante Spain
| | - Franck Albert
- Department of CardiologyCentre Hospitalier de ChartresChartres France
| |
Collapse
|
25
|
Tirado-Conte G, Rodés-Cabau J, Rodríguez-Olivares R, Barbanti M, Lhermusier T, Amat-Santos I, Toggweiler S, Cheema AN, Muñoz-García AJ, Serra V, Giordana F, Veiga G, Jiménez-Quevedo P, Campelo-Parada F, Loretz L, Todaro D, del Trigo M, Hernández-García JM, García del Blanco B, Bruno F, de la Torre Hernández JM, Stella P, Tamburino C, Macaya C, Nombela-Franco L. Clinical Outcomes and Prognosis Markers of Patients With Liver Disease Undergoing Transcatheter Aortic Valve Replacement. Circ Cardiovasc Interv 2018; 11:e005727. [DOI: 10.1161/circinterventions.117.005727] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2017] [Accepted: 01/16/2018] [Indexed: 02/06/2023]
Abstract
Background—
Chronic liver disease is a known risk factor for perioperative morbidity and mortality in patients undergoing cardiac surgery. Very little data exist about such patients treated with transcatheter aortic valve replacement (TAVR). Our objective was to evaluate early and late clinical outcomes in a large cohort of patients with liver disease undergoing TAVR and to determine predictive factors of mortality among these patients.
Methods and Results—
This multicenter study collected data from 114 patients with chronic liver disease who underwent TAVR in 12 institutions. Perioperative and long-term outcomes were compared with a cohort of 1118 patients without liver disease after a propensity score–matching analysis (114 matched pairs). In-hospital mortality and vascular and bleeding complications were similar between matched groups. Acute kidney injury was more common in liver disease group (30.8% versus 13.5%;
P
=0.010). Although cardiovascular mortality was similar between groups (9.4% versus 6.5%;
P
=0.433) at 2-year follow-up, noncardiac mortality was higher in the liver group (26.4% versus 14.8%;
P
=0.034). Lower glomerular filtration rate (hazard ratio, 1.10, for each decrease of 5 mL/min in estimated glomerular filtration rate; 95% confidence interval, 1.03–1.17;
P
=0.005) and Child-Pugh class B or C (hazard ratio, 3.11; 95% confidence interval, 1.47–6.56;
P
=0.003) were the predictors of mortality in patients with chronic liver disease, with a mortality rate of 83.2% at 2-year follow-up in patients with both factors (estimated glomerular filtration rate <60 mL/min and Child-Pugh B or C).
Conclusions—
These findings suggested that TAVR is a feasible treatment for severe aortic stenosis in patients with early-stage liver disease or as bridge therapy before a curative treatment of the hepatic condition. Patients with Child-Pugh class B-C, especially in combination with renal impairment, had a very low survival rate, and TAVR should be carefully considered to avoid a futile treatment. These results may contribute to improve the clinical decision-making process and management in patients with liver disease.
Collapse
Affiliation(s)
- Gabriela Tirado-Conte
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Josep Rodés-Cabau
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Ramón Rodríguez-Olivares
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Marco Barbanti
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Thibault Lhermusier
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Ignacio Amat-Santos
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Stefan Toggweiler
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Asim N. Cheema
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Antonio J. Muñoz-García
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Vicenc Serra
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Francesca Giordana
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Gabriela Veiga
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Pilar Jiménez-Quevedo
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Francisco Campelo-Parada
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Lucca Loretz
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Denise Todaro
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - María del Trigo
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - José M. Hernández-García
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Bruno García del Blanco
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Francesco Bruno
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - José M. de la Torre Hernández
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Pieter Stella
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Corrado Tamburino
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Carlos Macaya
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| | - Luis Nombela-Franco
- From the Cardiovascular Institute, Hospital Clínico San Carlos and Universidad Complutense, IdISSC, Madrid, Spain (G.T.-C., P.J.-Q., M.d.T., C.M., L.N.-F.); Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec City, Canada (J.R.-C., F.C.-P., M.d.T.); Department of Cardiology, Utrecht Medisch Centrum, the Netherlands (R.R.-O., P.S.); Department of Cardiology, Ferrarotto Hospital, University of Catania, Italy (M.B., D.T., C.T.); Department of Cardiology, Rangueil
| |
Collapse
|
26
|
Alfonso F, Cuesta J, Pérez-Vizcayno MJ, García del Blanco B, Rivero F. Reply. JACC Cardiovasc Interv 2018; 11:221-222. [DOI: 10.1016/j.jcin.2017.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Accepted: 11/08/2017] [Indexed: 11/30/2022]
|
27
|
Wassef AW, Alnasser S, Rodes-Cabau J, Webb JG, Barbanti M, Liu Y, Muñoz-García AJ, Tamburino C, Dager AE, Serra V, Amat-Santos IJ, Al Lawati H, Urena M, Alonso Briales JH, Benitez LM, del Blanco BG, Roman AS, Bagai A, Buller CE, Peterson MD, Cheema AN. Institutional experience and outcomes of transcatheter aortic valve replacement: Results from an international multicentre registry. Int J Cardiol 2017; 245:222-227. [DOI: 10.1016/j.ijcard.2017.07.079] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/16/2016] [Revised: 05/25/2017] [Accepted: 07/18/2017] [Indexed: 10/19/2022]
|
28
|
Alfonso F, Cuesta J, Pérez-Vizcayno MJ, García del Blanco B, Rumoroso JR, Bosa F, Pérez de Prado A, Masotti M, Moreno R, Cequier A, Gutiérrez H, García Touchard A, López-Mínguez JR, Zueco J, Martí V, Velázquez M, Morís C, Bastante T, García-Guimaraes M, Rivero F, Fernández C. Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis. JACC Cardiovasc Interv 2017; 10:1841-1851. [DOI: 10.1016/j.jcin.2017.06.064] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Revised: 06/22/2017] [Accepted: 06/22/2017] [Indexed: 10/19/2022]
|
29
|
Auffret V, Webb JG, Eltchaninoff H, Muñoz-García AJ, Himbert D, Tamburino C, Nombela-Franco L, Nietlispach F, Morís C, Ruel M, Dager AE, Serra V, Cheema AN, Amat-Santos IJ, de Brito FS, Lemos PA, Abizaid A, Sarmento-Leite R, Dumont E, Barbanti M, Durand E, Alonso Briales JH, Vahanian A, Bouleti C, Immè S, Maisano F, del Valle R, Benitez LM, García del Blanco B, Puri R, Philippon F, Urena M, Rodés-Cabau J. Clinical Impact of Baseline Right Bundle Branch Block in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv 2017; 10:1564-1574. [DOI: 10.1016/j.jcin.2017.05.030] [Citation(s) in RCA: 63] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Revised: 05/01/2017] [Accepted: 05/05/2017] [Indexed: 10/19/2022]
|
30
|
García del Blanco B, Jiménez Quevedo P, Diaz J, Hernández F, Rumoroso J, Sabaté M, de la Torre Hernandez JM, Serrador A, Pérez de Prado A, Goicolea J, Trillo R, Pan M. Spain: coronary and structural heart interventions from 2010 to 2015. EUROINTERVENTION 2017; 13:Z64-Z69. [DOI: 10.4244/eij-d-16-00834] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
31
|
Alfonso F, Pérez-Vizcayno MJ, García del Blanco B, García-Touchard A, López-Mínguez JR, Sabaté M, Zueco J, Melgares R, Hernández R, Moreno R, Domínguez A, Sanchís J, Moris C, Moreu J, Cequier A, Romaguera R, Rivero F, Cuesta J, Gonzalo N, Jiménez-Quevedo P, Cárdenas A, Fernández C. Usefulness of Drug-Eluting Balloons for Bare-Metal and Drug-Eluting In-Stent Restenosis (from the RIBS IV and V Randomized Trials). Am J Cardiol 2017; 119:983-990. [PMID: 28139220 DOI: 10.1016/j.amjcard.2016.12.006] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2016] [Revised: 12/19/2016] [Accepted: 12/19/2016] [Indexed: 11/26/2022]
Abstract
Treatment of patients with drug-eluting stent (DES) in-stent restenosis (ISR) is particularly challenging. We sought to compare results of drug-eluting balloons in patients with DES-ISR with those in patients with bare-metal stent (BMS) ISR. A pooled analysis of the Restenosis Intra-Stent: Drug-Eluting Balloon versus Everolimus-Eluting Stent IV and V randomized trials was performed. Both trials had identical inclusion and exclusion criteria. Results of drug-eluting balloons in 95 patients with BMS-ISR and 154 patients with DES-ISR were compared. Patients with DES-ISR were more frequently diabetics, presented more often as an acute coronary syndrome and had more severe lesions and more frequently a focal pattern, including edge-ISR. Late angiographic findings (92% of eligible patients), including minimal lumen diameter (1.80 ± 0.6 vs 2.01 ± 0.6 mm, p = 0.001; absolute mean difference 0.21 mm; 95% confidence interval 0.04 to 0.38; p = 0.014) and restenosis rate (19% vs 9.5%, p <0.05) were poorer in DES-ISR. Results were consistent across 10 prespecified subgroups. Moreover, on multiple linear regression analysis, minimal lumen diameter at follow-up remained significantly smaller in patients with DES-ISR after adjusting for potential confounders (adjusted absolute mean difference 0.17 mm; 95% confidence interval 0.04 to 0.41; p = 0.019). Finally, at 1-year clinical follow-up (100% of patients), rates of target vessel revascularization (16% vs 6%, p = 0.02) and of the main combined clinical end point (18% vs 8%, p = 0.03) were significantly higher in patients treated for DES-ISR. In conclusion, this study confirms the efficacy of DEB for patients with ISR. However, the long-term clinical and angiographic results of DEB are poorer in patients with DES-ISR than in those with BMS-ISR. (ClinicalTrials.govIdentifier:NCT01239953&NCT01239940).
Collapse
|
32
|
García-Touchard A, Goicolea J, Sabaté M, Alfonso F, Ruiz-Salmerón R, Bethencourt A, Gonzalo N, Miranda F, García del Blanco B, Jiménez-Mazuecos J, Melgares R, Martínez-Romero P, Hernandez-García J, Lezaún R, Bullones J, Fernández-Portales J, Rumoroso J, Ortas R, Valdés M, Trillo R, Brugaletta S, Otzuki S, Hernández Pérez FJ, Alonso-Pulpón L. A randomised trial of paclitaxel-eluting balloon after bare metal stent implantation vs. bare metal stent in ST-elevation myocardial infarction (the PEBSI study). EUROINTERVENTION 2017; 12:1587-1594. [DOI: 10.4244/eij-d-16-00128] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
33
|
Hernández Hernández F, de la Torre Hernández JM, Rumoroso Cuevas JR, García del Blanco B, Zunzunegui Martínez JL, Trillo Nouche R. Selección de temas de actualidad en cardiología intervencionista 2015. Rev Esp Cardiol 2016. [DOI: 10.1016/j.recesp.2015.12.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
34
|
Wassef A, Rodes-Cabau J, Webb J, Muñoz-García AJ, Tamburino C, Dager A, Serra V, Amat-Santos I, Dumont E, Lawati HA, Alnasser S, Urena M, Barbanti M, Benitez L, Briales JHA, del Blanco BG, Buller C, Peterson M, Cheema A. THE EFFECT OF PROCEDURAL VOLUME AND EXPERIENCE ON CLINICAL OUTCOMES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: RESULTS FROM THE INTERNATIONAL MULTICENTER TAVR REGISTRY. J Am Coll Cardiol 2016. [DOI: 10.1016/s0735-1097(16)30248-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
35
|
Alfonso F, Pérez-Vizcayno MJ, García del Blanco B, García-Touchard A, Masotti M, López-Minguez JR, Iñiguez A, Zueco J, Velazquez M, Cequier A, Lázaro-García R, Martí V, Moris C, Urbano-Carrillo C, Bastante T, Rivero F, Cárdenas A, Gonzalo N, Jiménez-Quevedo P, Fernández C. Comparison of the Efficacy of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With In-Stent Restenosis (from the RIBS IV and V Randomized Clinical Trials). Am J Cardiol 2016; 117:546-554. [PMID: 26725102 DOI: 10.1016/j.amjcard.2015.11.042] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Revised: 11/18/2015] [Accepted: 11/18/2015] [Indexed: 10/22/2022]
Abstract
Treatment of patients with in-stent restenosis (ISR) remains a challenge. This study sought to compare the efficacy of everolimus-eluting stents (EESs) and drug-eluting balloons (DEBs) with paclitaxel in patients with ISR. A pooled analysis of the Restenosis Intra-Stent of Drug-Eluting Stents: Drug-Eluting Balloon vs Everolimus-Eluting Stent (RIBS IV) and Restenosis Intra-Stent of Bare-Metal Stents: Drug-Eluting Balloon vs Everolimus-Eluting Stent (RIBS V) randomized trials was performed using patient-level data. In both trials, EESs were compared with DEBs in patients with ISR (RIBS V included 189 patients with bare-metal ISR; RIBS IV included 309 patients with drug-eluting ISR). Inclusion and exclusion criteria were identical in both trials. A total of 249 patients were allocated to EES and 249 to DEB. Clinical follow-up at 1 year was obtained in all (100%) patients and late angiography (median 249 days) in 91% of eligible patients. Compared with patients treated with DEBs, patients treated with EESs obtained better short-term results (postprocedural minimal lumen diameter 2.28 ± 0.5 vs 2.12 ± 0.4 mm, p <0.0001). At follow-up, patients treated with EESs had larger in-segment minimal lumen diameter (primary end point 2.16 ± 0.7 vs 1.88 ± 0.6 mm, p <0.0001; absolute mean difference 0.28 mm; 95% confidence interval [CI] 0.16 to 0.40) and net lumen gain (1.33 ± 0.6 vs 1.00 ± 0.7 mm, p <0.0001) and had lower %diameter stenosis (19 ± 21% vs 28 ± 22%, p <0.0001) and binary restenosis rate (8.7% vs 15.7%, p = 0.02). Consistent results were observed in the in-lesion analysis. No interactions were found between the underlying stent type and treatment effects. At 1-year clinical follow-up, the composite of cardiac death, myocardial infarction, and target vessel revascularization was significantly reduced in the EES arm (8.8% vs 14.5%, p = 0.03; hazard ratio 0.59, 95% CI 0.31 to 0.94) mainly driven by a lower need for target vessel revascularization (6% vs 12.4%, p = 0.01, hazard ratio 0.46, 95% CI 0.25 to 0.86). This pooled analysis of the RIBS IV and RIBS V randomized trials demonstrates the superiority of EES over DEB in the treatment of patients with ISR.
Collapse
|
36
|
Sambola A, Mutuberría M, García del Blanco B, Alonso A, Barrabés JA, Bueno H, Alfonso F, Cequier A, Zueco J, Rodríguez-Leor O, Tornos P, García-Dorado D. Impact of Triple Therapy in Elderly Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. PLoS One 2016; 11:e0147245. [PMID: 26808678 PMCID: PMC4726489 DOI: 10.1371/journal.pone.0147245] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2015] [Accepted: 01/03/2016] [Indexed: 11/29/2022] Open
Abstract
Background and Purpose Selecting an ideal antithrombotic therapy for elderly patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) can be challenging since they have a higher thromboembolic and bleeding risk than younger patients. The current study aimed to assess the efficacy and safety of triple therapy (TT: oral anticoagulation plus dual antiplatelet therapy: aspirin plus clopidogrel) in patients ≥75 years of age with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). Methods A prospective multicenter study was conducted from 2003 to 2012 at 6 Spanish teaching hospitals. A cohort study of consecutive patients with AF undergoing PCI and treated with TT or dual antiplatelet therapy (DAPT) was analyzed. All outcomes were evaluated at 1-year of follow-up. Results Five hundred and eighty-five patients, 289 (49%) of whom were ≥75 years of age (79.6±3.4 years; 33% women) were identified. TT was prescribed in 55.9% of patients at discharge who had a higher thromboembolic risk (CHA2DS2VASc score: 4.23±1.51 vs 3.76±1.40, p = 0.007 and a higher bleeding risk (HAS-BLED ≥3: 88.6% vs 79.2%, p = 0.02) than those on DAPT. Therefore, patients on TT had a lower rate of thromboembolism than those on DAPT (0.6% vs 6.9%, p = 0.004; HR 0.08, 95% CI: 0.01–0.70, p = 0.004). Major bleeding events occurred more frequently in patients on TT than in those on DAPT (11.7% vs 2.4%, p = 0.002; HR 5.2, 95% CI: 1.53–17.57, p = 0.008). The overall mortality rate was similar in both treatment groups (11.9% vs 13.9%, p = 0.38); however, after adjustment for confounding variables, TT was associated with a reduced mortality rate (HR 0.33, 95% CI: 0.12–0.86, p = 0.02). Conclusions In elderly patients with AF undergoing PCI, the use of TT compared to DAPT was associated with reduced thromboembolism and mortality rates, although a higher rate of major bleeding.
Collapse
Affiliation(s)
- Antonia Sambola
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
- * E-mail:
| | - Maria Mutuberría
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Bruno García del Blanco
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Albert Alonso
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - José A. Barrabés
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Héctor Bueno
- Cardiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - Fernando Alfonso
- Cardiology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - Angel Cequier
- Cardiology Department, Hospital Universitari de Bellvitge, L’Hospitalet del Llobregat, Barcelona, Spain
| | - Javier Zueco
- Cardiology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Oriol Rodríguez-Leor
- Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - Pilar Tornos
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - David García-Dorado
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
37
|
Sambola A, Mutuberría M, García del Blanco B, Alonso A, Barrabés JA, Alfonso F, Bueno H, Cequier A, Zueco J, Rodríguez-Leor O, Bosch E, Tornos P, García-Dorado D. Effects of Triple Therapy in Patients With Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Regarding Thromboembolic Risk Stratification. Circ J 2016; 80:354-62. [DOI: 10.1253/circj.cj-15-0923] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Antonia Sambola
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona
| | - Maria Mutuberría
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona
| | - Bruno García del Blanco
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona
| | - Albert Alonso
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona
| | - José A. Barrabés
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona
| | - Fernando Alfonso
- Cardiology Department, Hospital Universitario Clínico San Carlos
| | - Héctor Bueno
- Cardiology Department, Hospital General Universitario Gregorio Marañón
| | - Angel Cequier
- Cardiology Department, Hospital Universitari de Bellvitge
| | - Javier Zueco
- Cardiology Department, Hospital Universitario Marqués de Valdecilla
| | | | - Eduard Bosch
- Cardiology Department, Hospital Universitari Parc Taulí
| | - Pilar Tornos
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona
| | - David García-Dorado
- Cardiology Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona
| |
Collapse
|
38
|
García del Blanco B, Hernández Hernández F, Rumoroso Cuevas JR, Trillo Nouche R. Registro Español de Hemodinámica y Cardiología Intervencionista. XXIV Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2014). Rev Esp Cardiol 2015. [DOI: 10.1016/j.recesp.2015.09.007] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
39
|
Ribeiro HB, Nombela-Franco L, Muñoz-García AJ, Lemos PA, Amat-Santos I, Serra V, de Brito FS, Abizaid A, Sarmento-Leite R, Puri R, Cheema AN, Ruel M, Nietlispach F, Maisano F, Moris C, del Valle R, Urena M, Abdul Jawad Altisent O, del Trigo M, Campelo-Parada F, Jimenez Quevedo P, Alonso-Briales JH, Gutiérrez H, García del Blanco B, Perin MA, Siqueira D, Bernardi G, Dumont É, Côté M, Pibarot P, Rodés-Cabau J. Predictors and Impact of Myocardial Injury After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2015; 66:2075-2088. [DOI: 10.1016/j.jacc.2015.08.881] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/27/2015] [Revised: 08/21/2015] [Accepted: 08/28/2015] [Indexed: 10/22/2022]
|
40
|
Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García del Blanco B, García-Touchard A, López-Minguéz JR, Benedicto A, Masotti M, Zueco J, Iñiguez A, Velázquez M, Moreno R, Mainar V, Domínguez A, Pomar F, Melgares R, Rivero F, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C. A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents. J Am Coll Cardiol 2015; 66:23-33. [DOI: 10.1016/j.jacc.2015.04.063] [Citation(s) in RCA: 212] [Impact Index Per Article: 23.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2015] [Revised: 04/17/2015] [Accepted: 04/20/2015] [Indexed: 12/15/2022]
|
41
|
Alfonso F, Pérez-Vizcayno MJ, Cárdenas A, García del Blanco B, García-Touchard A, López-Minguéz JR, Rivero F, Masotti M, Zueco J, Cequier A, Morís C, Fernández-Ortíz A, Escaned J, Jiménez-Quevedo P, Gonzalo N, Fernández C, Macaya C. Rationale and design of the RIBS IV randomised clinical trial (drug-eluting balloons versus everolimus-eluting stents for patients with drug-eluting stent restenosis). EUROINTERVENTION 2015; 11:336-42. [DOI: 10.4244/eijy14m09_07] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
42
|
Nombela-Franco L, Eltchaninoff H, Zahn R, Testa L, Leon MB, Trillo-Nouche R, D'Onofrio A, Smith CR, Webb J, Bleiziffer S, De Chiara B, Gilard M, Tamburino C, Bedogni F, Barbanti M, Salizzoni S, García del Blanco B, Sabaté M, Moreo A, Fernández C, Ribeiro HB, Amat-Santos I, Urena M, Allende R, García E, Macaya C, Dumont E, Pibarot P, Rodés-Cabau J. Clinical impact and evolution of mitral regurgitation following transcatheter aortic valve replacement: a meta-analysis. Heart 2015; 101:1395-405. [PMID: 26060121 DOI: 10.1136/heartjnl-2014-307120] [Citation(s) in RCA: 97] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Accepted: 05/12/2015] [Indexed: 11/03/2022] Open
Abstract
OBJECTIVES Mitral regurgitation (MR) is a common entity in patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), but its influence on outcomes remains controversial. The purpose of this meta-analysis was to assess the clinical impact of and changes in significant (moderate-severe) MR in patients undergoing TAVR, overall and according to valve design (self-expandable (SEV) vs balloon-expandable (BEV)). METHODS All national registries and randomised trials were pooled using meta-analytical guidelines to establish the impact of moderate-severe MR on mortality after TAVR. Studies reporting changes in MR after TAVR on an individual level were electronically searched and used for the analysis. RESULTS Eight studies including 8015 patients (SEV: 3474 patients; BEV: 4492 patients) were included in the analysis. The overall 30-day and 1-year mortality was increased in patients with significant MR (OR 1.49, 95% CI 1.16 to 1.92; HR 1.32, 95% CI 1.12 to 1.55, respectively), but a significant heterogeneity across studies was observed (p<0.05). The impact of MR on mortality was not different between SEV and BEV in meta-regression analysis for 30-day (p=0.360) and 1-year (p=0.388) mortality. Changes in MR over time were evaluated in nine studies including 1278 patients. Moderate-severe MR (SEV: 326 patients; BEV: 192 patients) improved in 50.5% of the patients at a median follow-up of 180 (30-360) days after TAVR, and the degree of improvement was greater in patients who had received a BEV (66.7% vs 40.8% in the SEV group, p=0.001). CONCLUSIONS Concomitant moderate-severe MR was associated with increased early and late mortality following TAVR. A significant improvement in MR severity was detected in half of the patients following TAVR, and the degree of improvement was greater in those patients who had received a BEV.
Collapse
Affiliation(s)
- Luis Nombela-Franco
- Quebec Heart & Lung Institute, Quebec city, Quebec, Canada Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain
| | - Hélène Eltchaninoff
- Cardiology Department, Charles Nicolle Hospital, University of Rouen, Rouen, France
| | - Ralf Zahn
- Abteilung für Kardiologie, Herzzentrum Ludwigshafen, Ludwigshafen, Germany
| | - Luca Testa
- Cardiology Department, Instituto Clinico S. Ambrogio, Milan, Italy
| | - Martin B Leon
- Columbia University Medical Center/New York-Presbyterian Hospital, New York, USA
| | | | | | - Craig R Smith
- Columbia University Medical Center/New York-Presbyterian Hospital, New York, USA
| | - John Webb
- St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada
| | | | | | - Martine Gilard
- Department of Cardiology, La Cavale Blanche Hospital, Brest, France
| | | | | | | | - Stefano Salizzoni
- Department of Surgical Sciences Torino, Città della Salute e della Scienza Hospital, Molinette, Torino, Italy
| | | | - Manel Sabaté
- Cardiology Department, Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain
| | - Antonella Moreo
- Cardiology Department, Niguarda Ca' Granda Hospital, Milan, Italy
| | | | | | | | - Marina Urena
- Quebec Heart & Lung Institute, Quebec city, Quebec, Canada
| | | | - Eulogio García
- Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain
| | - Carlos Macaya
- Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain
| | - Eric Dumont
- Quebec Heart & Lung Institute, Quebec city, Quebec, Canada
| | | | | |
Collapse
|
43
|
Duran J, Olavarría PS, Mola M, Götzens V, Carballo J, Pelegrina EM, Petit M, Abdul-Jawad O, Otaegui I, del Blanco BG, García-Dorado D, Reig J, Cordero A, de Anta JM. Genetic association study of coronary collateral circulation in patients with coronary artery disease using 22 single nucleotide polymorphisms corresponding to 10 genes involved in postischemic neovascularization. BMC Cardiovasc Disord 2015; 15:37. [PMID: 25959001 PMCID: PMC4493944 DOI: 10.1186/s12872-015-0027-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Accepted: 04/21/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Collateral growth in patients with coronary artery disease (CAD) is highly heterogeneous. Although multiple factors are thought to play a role in collateral development, the contribution of genetic factors to coronary collateral circulation (CCC) is largely unknown. The goal of this study was to assess whether functional single nucleotide polymorphisms (SNPs) in genes involved in vascular growth are associated with CCC. METHODS 677 consecutive CAD patients were enrolled in the study and their CCC was assessed by the Rentrop method. 22 SNPs corresponding to 10 genes involved in postischemic neovascularization were genotyped and multivariate logistic regression models were adjusted using clinically relevant variables to estimate odds ratios and used to examine associations of allelic variants, genotypes and haplotypes with CCC. RESULTS Statistical analysis showed that the HIF1A rs11549465 and rs2057482; VEGFA rs2010963, rs1570360, rs699947, rs3025039 and rs833061; KDR rs1870377, rs2305948 and rs2071559; CCL2 rs1024611, rs1024610, rs2857657 and rs2857654; NOS3 rs1799983; ICAM1 rs5498 and rs3093030; TGFB1 rs1800469; CD53 rs6679497; POSTN rs3829365 and rs1028728; and LGALS2 rs7291467 polymorphisms, as well as their haplotype combinations, were not associated with CCC (p < 0.05). CONCLUSIONS We could not validate in our cohort the association of the NOS3 rs1799983, HIF1A rs11549465, VEGFA rs2010963 and rs699947, and LGALS2 rs7291467 variants with CCC reported by other authors. A validated SNP-based genome-wide association study is required to identify polymorphisms influencing CCC.
Collapse
Affiliation(s)
- Joan Duran
- Unitat d'Anatomia i Embriologia Humanes, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina, Campus de Ciències de la Salut de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
| | - Pilar Sánchez Olavarría
- Unitat d'Anatomia i Embriologia Humanes, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina, Campus de Ciències de la Salut de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, 08907, Spain. .,Departamento de Estadística, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso, Chile.
| | - Marina Mola
- Unitat d'Anatomia i Embriologia Humanes, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina, Campus de Ciències de la Salut de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, 08907, Spain. .,Neurovascular Research Group (NEUVAS), Institut Municipal d'Investigació Mèdica. Hospital del Mar, PRBB, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain.
| | - Víctor Götzens
- Unitat d'Anatomia i Embriologia Humanes, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina, Campus de Ciències de la Salut de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
| | - Julio Carballo
- Department of Cardiology and Hemodynamics, Centre Cardiovascular Sant Jordi, Barcelona, Spain.
| | - Eva Martín Pelegrina
- Department of Cardiology and Hemodynamics, Centre Cardiovascular Sant Jordi, Barcelona, Spain.
| | - Màrius Petit
- Department of Cardiology and Hemodynamics, Centre Cardiovascular Sant Jordi, Barcelona, Spain.
| | - Omar Abdul-Jawad
- Department of Cardiology, Hospital Mútua de Terrassa, Terrassa, Barcelona, Spain.
| | - Imanol Otaegui
- Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
| | | | - David García-Dorado
- Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
| | - Josep Reig
- Departament of Morphological Sciences, Universitat Autònoma de Barcelona, Bellaterra, Cerdanyola del Vallès, Barcelona, Spain.
| | - Alex Cordero
- Unitat d'Anatomia i Embriologia Humanes, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina, Campus de Ciències de la Salut de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, 08907, Spain. .,Àrea Epigenetics and Cancer Biology Area, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
| | - Josep Maria de Anta
- Unitat d'Anatomia i Embriologia Humanes, Departament de Patologia i Terapèutica Experimental, Facultat de Medicina, Campus de Ciències de la Salut de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Barcelona, 08907, Spain.
| |
Collapse
|
44
|
Urena M, Hayek S, Cheema AN, Serra V, Amat-Santos IJ, Nombela-Franco L, Ribeiro HB, Allende R, Paradis JM, Dumont E, Thourani VH, Babaliaros V, Francisco Pascual J, Cortés C, del Blanco BG, Philippon F, Lerakis S, Rodés-Cabau J. Arrhythmia Burden in Elderly Patients With Severe Aortic Stenosis as Determined by Continuous Electrocardiographic Recording. Circulation 2015; 131:469-77. [PMID: 25466975 DOI: 10.1161/circulationaha.114.011929] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
This study sought to evaluate the prevalence of previously undiagnosed arrhythmias in candidates for transcatheter aortic valve replacement (TAVR) and to determine the impact on therapy changes and arrhythmic events after the procedure.
Methods and Results—
A total of 435 candidates for TAVR underwent 24-hour continuous ECG monitoring the day before the procedure. Newly diagnosed arrhythmias were observed in 70 patients (16.1%) before TAVR: paroxysmal atrial fibrillation (AF)/atrial tachycardia (AT) in 28, advanced atrioventricular block or severe bradycardia in 24, nonsustained ventricular tachycardia in 26, and intermittent left bundle-branch block in 3 patients. All arrhythmic events but one were asymptomatic and led to a therapy change in 43% of patients. In patients without known AF/AT, the occurrence of AF/AT during 24-hour ECG recording was associated with a higher rate of 30-day cerebrovascular events (7.1% versus 0.4%;
P
=0.030). Among the 53 patients with new-onset AF/AT after TAVR, 30.2% had newly diagnosed paroxysmal AF/AT before the procedure. In patients who needed permanent pacemaker implantation after the procedure (n=35), 31.4% had newly diagnosed advanced atrioventricular block or severe bradycardia before TAVR. New-onset persistent left bundle-branch block after TAVR occurred in 37 patients, 8.1% of whom had intermittent left bundle-branch block before the procedure.
Conclusions—
Newly diagnosed arrhythmias were observed in approximately a fifth of TAVR candidates, led to a higher rate of cerebrovascular events, and accounted for a third of arrhythmic events after the procedure. This high arrhythmia burden highlights the importance of an early diagnosis of arrhythmic events in such patients to implement the appropriate therapeutic measures earlier.
Collapse
Affiliation(s)
- Marina Urena
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Salim Hayek
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Asim N. Cheema
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Vicenç Serra
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Ignacio J. Amat-Santos
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Luis Nombela-Franco
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Henrique B. Ribeiro
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Ricardo Allende
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Jean-Michel Paradis
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Eric Dumont
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Vinod H. Thourani
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Vasilis Babaliaros
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Jaume Francisco Pascual
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Carlos Cortés
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Bruno García del Blanco
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - François Philippon
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Stamatios Lerakis
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| | - Josep Rodés-Cabau
- From the Quebec Heart and Lung Institute, Laval University, Quebec, Quebec, Canada (M.U., I.J.A.-S., H.B.R., R.A., J.P., E.D., F.P., J.R.-C.); Emory University School of Medicine, Atlanta, GA (S.H., V.H.T., V.B., S.L.); St Michael’s Hospital, Toronto University, Toronto, Ontario, Canada (A.N.C.); Hospital Universitari Vall d’Hebron, Barcelona, Spain (V.S., J.F.P., B.G.d.B.); Hospital Clínico Universitario de Valladolid, Valladolid, Spain (I.J.A.-S., C.C.); and Hospital Clínico San Carlos de Madrid,
| |
Collapse
|
45
|
Urena M, Webb JG, Eltchaninoff H, Muñoz-García AJ, Bouleti C, Tamburino C, Nombela-Franco L, Nietlispach F, Moris C, Ruel M, Dager AE, Serra V, Cheema AN, Amat-Santos IJ, de Brito FS, Lemos PA, Abizaid A, Sarmento-Leite R, Ribeiro HB, Dumont E, Barbanti M, Durand E, Alonso Briales JH, Himbert D, Vahanian A, Immè S, Garcia E, Maisano F, del Valle R, Benitez LM, García del Blanco B, Gutiérrez H, Perin MA, Siqueira D, Bernardi G, Philippon F, Rodés-Cabau J. Late Cardiac Death in Patients Undergoing Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2015; 65:437-48. [DOI: 10.1016/j.jacc.2014.11.027] [Citation(s) in RCA: 172] [Impact Index Per Article: 19.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Revised: 10/28/2014] [Accepted: 11/04/2014] [Indexed: 11/29/2022]
|
46
|
García del Blanco B, Hernández Hernández F, Rumoroso Cuevas JR, Trillo Nouche R. Spanish Cardiac Catheterization and Coronary Intervention Registry. 23rd official report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2013). ACTA ACUST UNITED AC 2014; 67:1013-23. [PMID: 25455754 DOI: 10.1016/j.rec.2014.08.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Accepted: 08/17/2014] [Indexed: 11/30/2022]
Abstract
INTRODUCTION AND OBJECTIVES The Working Group on Cardiac Catheterization and Interventional Cardiology presents its yearly report on the data from the registry of the activity in Spain corresponding to 2013. METHODS The centers introduce their data online voluntarily and the information is analyzed by the Steering Committee of the Working Group on Cardiac Catheterization. RESULTS In 2013, 104 hospitals sent their data (72 public centers and 32 private). In all, 136 715 diagnostic studies were performed (120 358 coronary angiograms), with a slight decrease with respect to 2012, a reduction that was also observed in the rate, which was 2944 diagnostic studies per million population. A total of 65 912 interventional procedures were carried out during a phase of stability, for a rate of 1419 interventions per million population. Other techniques included the implantation of 99 417 stents and 1384 biodegradable intracoronary devices (64% of them drug-eluting devices). There were 18 337 procedures in acute myocardial infarction, for an increase of 7% with respect to 2012 and representing 27.8% of all the percutaneous coronary interventions. Radial access was the approach used in 71% of the diagnostic procedures and in 65% of the interventional procedures. The performance of renal denervation has nearly doubled with respect to 2012. For the first time, more than 1000 transcatheter aortic valve implantation procedures were carried out in 1 year, although the frequency increased only slightly (23%). CONCLUSIONS There continued to be a slight increase in the activity in cardiac catheterization in association with ST-segment elevation myocardial infarction, whereas, with the exception of recently introduced, highly specific procedures, the use of the remainder of the procedures, among them transcatheter aortic valve implantation, leveled off.
Collapse
Affiliation(s)
- Bruno García del Blanco
- Junta Directiva, Sección de Hemodinámica y Cardiología Intervencionista, Sociedad Española de Cardiología, Madrid, Spain.
| | - Felipe Hernández Hernández
- Junta Directiva, Sección de Hemodinámica y Cardiología Intervencionista, Sociedad Española de Cardiología, Madrid, Spain
| | - José Ramón Rumoroso Cuevas
- Junta Directiva, Sección de Hemodinámica y Cardiología Intervencionista, Sociedad Española de Cardiología, Madrid, Spain
| | - Ramiro Trillo Nouche
- Junta Directiva, Sección de Hemodinámica y Cardiología Intervencionista, Sociedad Española de Cardiología, Madrid, Spain
| |
Collapse
|
47
|
de la Torre Hernández JM, Alfonso F, Martin Yuste V, Sánchez Recalde Á, Jiménez Navarro MF, Pérez de Prado A, Hernández F, Abdul-Jawad Altisent O, Roura G, García Camarero T, Elizaga J, Calviño R, Moreu J, Bosa F, Jimenez Mazuecos J, Ruiz-Arroyo JR, García del Blanco B, Rumoroso JR. Comparación de stents de paclitaxel y stents de everolimus en el infarto agudo de miocardio con elevación del segmento ST e influencia de la trombectomía en los resultados. Estudio ESTROFA-IM. Rev Esp Cardiol 2014. [DOI: 10.1016/j.recesp.2014.01.020] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
48
|
Shiratori Y, Cola C, Brugaletta S, Alvarez-Contreras L, Martín-Yuste V, del Blanco BG, Ruiz-Salmeron R, Díaz J, Pinar E, Martí V, García-Picart J, Sabaté M. Randomized Comparison Between Polymer-Free Versus Polymer-Based Paclitaxel-Eluting Stent. Circ Cardiovasc Interv 2014; 7:312-21. [DOI: 10.1161/circinterventions.113.000800] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Yoshitaka Shiratori
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| | - Clarissa Cola
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| | - Salvatore Brugaletta
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| | - Luis Alvarez-Contreras
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| | - Victoria Martín-Yuste
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| | - Bruno García del Blanco
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| | - Rafael Ruiz-Salmeron
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| | - Jose Díaz
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| | - Eduardo Pinar
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| | - Vicens Martí
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| | - Juan García-Picart
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| | - Manel Sabaté
- From the Thorax Institute, Department of Cardiology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain (Y.S., S.B., M.S.); Cardiology Department, Interventional Cardiology Unit, Sant Pau Hospital, Barcelona, Spain (C.C., L.A.-C., V.M.-Y., V.M., J.G.-P.); Cardiology Department, Interventional Cardiology Unit, Vall d’Hebron Hospital, Barcelona, Spain (B.G.d.B.); Cardiology Department, Interventional Cardiology Unit, Virgen de Macarena
| |
Collapse
|
49
|
Rodríguez-Palomares JF, Figueras-Bellot J, Descalzo M, Moral S, Otaegui I, Pineda V, del Blanco BG, González-Alujas MT, Evangelista Masip A, García-Dorado D. Relation of ST-segment elevation before and after percutaneous transluminal coronary angioplasty to left ventricular area at risk, myocardial infarct size, and systolic function. Am J Cardiol 2014; 113:593-600. [PMID: 24484860 DOI: 10.1016/j.amjcard.2013.11.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/04/2013] [Revised: 11/05/2013] [Accepted: 11/05/2013] [Indexed: 10/26/2022]
Abstract
Electrocardiography is an excellent tool for decision making in patients with ST elevation myocardial infarction (STEMI). However, little is known on the correlation between its dynamic changes during primary percutaneous coronary intervention (PCI) and the anatomic information provided by cardiovascular magnetic resonance. The study aimed to assess the predictive value of dynamic ST-segment changes before and after PCI on myocardial area at risk (AAR), infarct size, and left ventricular function in patients with STEMI. Eighty-five consecutive patients with a first STEMI were included. An electrocardiogram was recorded before and after PCI at 1, 24, 48, 72, and 120 hours. Sum of ST elevation (sumSTE), the number of STE, and STE resolution (resSTE) were determined. Complete resSTE was defined as ≥70% resolution, and patients were classified into 3 groups: group 1 (resSTE 1 hour after PCI) n = 39; group 2 (resSTE 120 hour after PCI) n = 27; and group 3, without resSTE (n = 19). Cardiovascular magnetic resonance was performed during hospitalization and at 6 months. Left ventricular volumes, ejection fraction, AAR, infarct size, myocardial salvage index, and microvascular obstruction were determined. Before PCI, the number of STE and sumSTE were best associated with AAR (p <0.001). After PCI, lack of resSTE (group 3) was associated with larger infarct size, MVO, and lower myocardial salvage index. However, sumSTE at 120 hours after PCI best discriminated patients with larger infarct size, ventricular volumes, and lower ejection fraction during hospitalization and at follow-up. In conclusion, admission sumSTE best correlates with AAR, whereas sumSTE at 120 hours rather than early resSTE best correlates with infarct size and left ventricular volumes during hospitalization and at 6 months.
Collapse
|
50
|
Otsuki S, Shiratori Y, Brugaletta S, Cola C, García del Blanco B, Ruiz-Salmeron R, Díaz JF, Pinar E, Martí V, García-Picart J, Martín-Yuste V, Sabaté M. Edge Vascular Response After Polymer-Free vs. Polymer-Based Paclitaxel-Eluting Stent Implantation. Circ J 2014; 78:2657-64. [DOI: 10.1253/circj.cj-14-0345] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Shuji Otsuki
- Thorax Institute, Department of Cardiology, Hospital Clinic, IDIBAPS, University of Barcelona
| | - Yoshitaka Shiratori
- Thorax Institute, Department of Cardiology, Hospital Clinic, IDIBAPS, University of Barcelona
| | - Salvatore Brugaletta
- Thorax Institute, Department of Cardiology, Hospital Clinic, IDIBAPS, University of Barcelona
| | | | | | | | | | - Eduardo Pinar
- Department of Cardiology, Virgen de la Arrixaca Hospital
| | | | | | - Victoria Martín-Yuste
- Thorax Institute, Department of Cardiology, Hospital Clinic, IDIBAPS, University of Barcelona
| | - Manel Sabaté
- Thorax Institute, Department of Cardiology, Hospital Clinic, IDIBAPS, University of Barcelona
| |
Collapse
|